WIPO publishes Tryp Therapeutics patent application

The World Intellectual Property Organization WIPO has published clinical-stage biopharma Tryp Therapeutics Inc.'s international patent application for the intravenous administration of psilocybin and psilocin.

The improved method for the use of psychedelics patent application expands and strengthens the IP of TRP 8803 with an IV formulation of proprietary psilocybin and psilocin, to be administered together with psychotherapy, expected to enhance the psychedelics positive effects while reducing the limitations of other administration routes, including oral, nasal and sublingual.

Compared to oral administration, IV delivery of TRP 8803 can reduce the wait for the psychedelic experience onset to 30 minutes instead of typical 1 to 2 hours and achieve clinically validated blood levels of the psychedelic experience s onset to 30 minutes instead of typical 1 to 2 hours.

This last point needs to be further elaborated: when psilocybin is taken orally, its bioavailability can be reduced due to first-pass metabolism, due to the fact that this pro-drug needs first to be converted to psilocin to cross the blood brain barrier and induce the psychedelic state, all of which contributes to variable blood levels of the drug.

High blood levels are associated with side effects, while low blood levels may reduce efficacy. What IV administration does is to enable more precise dosing and optimal blood levels of psilocin, thereby improving the likelihood of clinical results and efficacy in a safe way.

The IV delivery technology could allow psychotherapists and patients to customize the psychedelic experience, as it would allow for better control of it by increasing or decreasing its strength and duration, or in the eventual appearance of side effects, to terminate the drug administration.

On Tryp's new therapeutic option, CEO Jim Gilligan said he believes that its ability to reduce the in-clinic time period might not only be appealing to patients but also result in a more scalable model for the broad and efficient roll out of psychedelic treatment. Robin Carhart-Harris, Ph. The D. chairman of the Tryp scientific advisory board said that by allowing rapid initiation and termination of the psychedelic experience, as well as providing highly refined control over the depth and duration of the experience, he believes that proprietary TRP 8803 holds a very strong potential to change the treatment paradigm for fibromyalgia and binge eating disorder, as well as certain types of depression, pain and obsessive-compulsive disorders.